Related Experiment Videos
[Ventricular arrhythmia and sudden cardiac death: the significance of left ventricular hypertrophy as risk factor]
14. Medizinische Klinik der Universität Erlangen-Nürnberg, BRD.
Insights
Left ventricular hypertrophy in hypertension increases cardiovascular risk. Reducing this hypertrophy may decrease ventricular arrhythmias, but further studies are needed to confirm prevention of sudden cardiac death.
Area of Science:
- Cardiology
- Hypertension Research
- Cardiac Electrophysiology
Context:
- Left ventricular hypertrophy (LVH) is a common adaptation in essential hypertension.
- LVH is an independent risk factor for cardiovascular morbidity and mortality, including sudden cardiac death.
- Hypertensive patients with LVH often exhibit increased premature ventricular beats.
Purpose:
- To explore the pathogenetic link between myocardial hypertrophy and ventricular arrhythmias.
- To discuss therapeutic strategies for ventricular arrhythmias in hypertensive patients with LVH.
- To evaluate the association between LVH regression and ventricular arrhythmia reduction.
Summary:
- Myocardial cell hypertrophy, left ventricular dilation, subendocardial stress, and impaired coronary reserve may link LVH to ventricular arrhythmias.
- Effective therapies for ventricular arrhythmias in this population include centrally sympatholytic agents, ACE inhibitors, beta-blockers, and calcium antagonists.
- Recent observations suggest LVH reduction correlates with decreased ventricular arrhythmia prevalence and severity.
Impact:
- Understanding the link between LVH and arrhythmias can guide therapeutic interventions.
- Regression of left ventricular mass is a primary therapeutic goal.
- Further prospective studies are essential to determine if reducing severe ventricular arrhythmias prevents sudden cardiac death in hypertensive patients with LVH.
Abstract:
Left ventricular hypertrophy is a frequent and early manifestation of cardiac structural adaptation in patients with essential hypertension. Prospective studies have clearly demonstrated that left ventricular hypertrophy represents a risk factor for cardiovascular morbidity and mortality, including sudden cardiac death. The increased risk is independent of the impact of high blood pressure and other risk factors on the cardiovascular system. Various clinical studies noted increased prevalence and severity of premature ventricular beats in hypertensive patients with left ventricular hypertrophy. Hypertrophy of myocardial cells, dilation of the left ventricle, increased stress of subendocardial myocardium and impaired coronary reserve are discussed as a possible pathogenetic link between myocardial hypertrophy and ventricular arrhythmias. Therapeutically, the primary goal for ventricular arrhythmias in hypertensive patients with left ventricular hypertrophy is regression of left ventricular mass. For this purpose, centrally sympatholytic agents, angiotensin converting enzyme inhibitors, betablockers and calcium antagonists have been found to be effective. Recently we observed that a reduction of left ventricular hypertrophy was associated with a decreased prevalence and severity of ventricular arrhythmias. Nevertheless, prospective studies are required to demonstrate whether reduction of severe ventricular arrhythmias helps to prevent sudden cardiac death due to left ventricular hypertrophy in hypertension.